HYTN Innovations Inc. (CSE: HYTN) and Peptide Development Labs Inc. (CSE: PEPT) have announced the closing of their previously announced statutory plan of arrangement, effective November 17, 2026. Concurrent with the closing, PDL completed a non-brokered private placement raising gross proceeds of approximately $3,000,000. The transaction results in HYTN shareholders receiving both new HYTN shares and PDL shares, while PDL prepares to begin trading on the CSE under the symbol "PEPT."

Key Points

  • HYTN Innovations Inc. (CSE: HYTN) and Peptide Development Labs Inc. (CSE: PEPT)
  • Statutory plan of arrangement closed effective 12:01 a.m. on November 17, 2026, with each HYTN share exchanged for one new HYTN share and 0.0555555555555556 of a PDL Common Share
  • PDL raised approximately $3,000,000 through 6,000,000 units priced at $0.50 per unit, with warrants exercisable at $0.75 for 24 months
  • Investors may be watching for PDL's anticipated CSE listing under "PEPT" and progress on its BPC-157 drug candidate development milestones

Share Exchange Mechanics for Existing HYTN Shareholders

Under the arrangement, each HYTN Common Share held at the effective time was exchanged for one new HYTN Common Share and 0.0555555555555556 of a PDL Common Share. Shareholders holding HYTN shares through a broker will have the exchange managed by their broker or applicable depositary. Registered shareholders must complete a letter of transmittal and deliver it to Odyssey Trust Company to receive Direct Registration System statements representing their new entitlements. Fractional PDL shares are rounded down to the next lesser whole number under the terms of the plan of arrangement.

PDL's $3 Million Private Placement to Fund Drug Development

Concurrent with the arrangement closing, PDL completed a non-brokered private placement of 6,000,000 units at $0.50 per unit, generating gross proceeds of approximately $3,000,000. Each unit comprises one PDL Common Share and one-half of one PDL Common Share purchase warrant. Each whole warrant is exercisable for one PDL Common Share at $0.75 for a period of 24 months. All securities issued carry a statutory hold period of four months and one day. Net proceeds are designated for development milestones including qualification and product setup, engineering and validation, regulatory and clinical readiness, and formal clinical development.

PDL's BPC-157 Peptide Candidate and Strategic Focus

PDL is a Canadian pharmaceutical development company advancing an investigational subcutaneous BPC-157 drug candidate targeting refractory ligament disorders. The company's approach centres on GMP-controlled supply, pharmaceutical quality systems, physician-led access, structured data generation, and formal clinical development. HYTN, meanwhile, continues to formulate, manufacture, market, and sell premium products containing psychoactive and psychotropic compounds including cannabis-derived cannabinoids. The two companies will operate as separate CSE-listed entities following the arrangement.